nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors
|
Campos, Susana |
|
|
27 |
12 |
p. 1881-1890 |
artikel |
2 |
Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)
|
Matsuoka, Hiroshi |
|
|
27 |
12 |
p. 1859-1866 |
artikel |
3 |
Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
|
Sugawara, Shunichi |
|
|
27 |
12 |
p. 1828-1838 |
artikel |
4 |
Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series
|
Iwasawa, Tomohiro |
|
|
27 |
12 |
p. 1867-1873 |
artikel |
5 |
Combining nutritional status with TNM stage: a physiological update on gastric cancer staging for improving prognostic accuracy in elderly patients
|
Sugawara, Kotaro |
|
|
27 |
12 |
p. 1849-1858 |
artikel |
6 |
Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study)
|
Shoji, Tadahiro |
|
|
27 |
12 |
p. 1874-1880 |
artikel |
7 |
Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
|
Sugawara, Shunichi |
|
|
27 |
12 |
p. 1839-1840 |
artikel |
8 |
First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048
|
Takahashi, Shunji |
|
|
27 |
12 |
p. 1805-1817 |
artikel |
9 |
Functional outcomes at PICU discharge in hemato-oncology children at a tertiary oncology center in Hong Kong
|
Leung, Karen K. Y. |
|
|
27 |
12 |
p. 1904-1915 |
artikel |
10 |
List of reviewers 2021–2022
|
|
|
|
27 |
12 |
p. 1916-1919 |
artikel |
11 |
Long non-coding RNA NR2F2-AS1 regulates human osteosarcoma growth and metastasis through miR-425-5p-mediated HMGB2
|
Ye, Jia |
|
|
27 |
12 |
p. 1891-1903 |
artikel |
12 |
Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302
|
Kasai, Takashi |
|
|
27 |
12 |
p. 1841-1848 |
artikel |
13 |
Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study
|
Kondo, Shunsuke |
|
|
27 |
12 |
p. 1795-1804 |
artikel |
14 |
Tumor–stroma ratio can predict lymph-node metastasis in cT1/2N0 oral tongue squamous cell carcinoma independent of tumor budding grade
|
Sakai, Toshihiko |
|
|
27 |
12 |
p. 1818-1827 |
artikel |